Plasma GH responses to GHRH, arginine, L-dopa, pyridostigmine, sequential administrations of GHRH and combined administration of PD and GHRH in Turner's syndrome

Journal of Endocrinological Investigation

Volumn 21, Issue 2, 1998, Pages 72-77

  Hanew, K ^a,b   Tanaka, A ^a   Utsumi, A ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hanew Clinic   (Japan)

Author keywords

GH; GHRH; Pyridostigmine; TSH; Turner's syndrome

Indexed keywords

ARGININE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LEVODOPA; PYRIDOSTIGMINE; SOMATOSTATIN; THYROTROPIN;

ADOLESCENT; ARTICLE; BODY FAT; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPOTHALAMUS; ORAL DRUG ADMINISTRATION; SCHOOL CHILD; SOMATIC CELL; THYROTROPIN BLOOD LEVEL; TURNER SYNDROME;

EID: 0031896952     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350318     Document Type: Article

References (33)

1. Meadow S.R., Boucher B.A., Mashiter K., King M.N.R., Stimmler L. Growth hormone secretion in subjects with ovarian dysgenesis and Turner's syndrome. Arch. Dis. Child. 43: 595, 1968.
2. Lanes R., Brito S., Suniaga M., Moncada G., Borges M. Growth hormone secretion in pubertal age patient with Turner's syndrome. J. Clin. Endocrinol. Metab. 71:770, 1990.
3. Wit J.M., Massarano A.A., Kamp G.A., Hindmarsh P.C., Van Es A., Brook C.G.D., Preece M.A., Matthews D.R. Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinol. (Copenh) 127: 7,1992.
4. Holl R.W., Kunze D., Blum W.F., Benz R., Etzrodt H. Heinze E. The somatotropin-somatomedin axis in adult patients with Turner's syndrome: Measurement of stimulated GH, GH-BP, IGF-I, IGF-II and IGFBP-3 in 25 patients. Horm. Res. 39:30, 1993.
5. Cianfani S., Vaccaro F., Pasquino A.M., Marchione S.A., Passeri F., Spadoni G.L., Bernardini S., Spagnoli A., Bosherini B. Reduced growth hormone secretion in Turner's syndrome: Is body weight a key factor? Horm. Res. 41: 27, 1994.
6. Cappa M., Loche S., Borrelli P., Corda R., Marini R., Porcedda C., Pintor C. Growth hormone response to growth hormone releasing hormone 1-40 in Turner's syndrome. Horm. Res. 27: 1, 1987.
7. Zadik Z., Landau H., Chen M., Altman Y., Lieberman E. Assessment of growth hormone (GH) axis in Turner's syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-l, plasma GH-binding activity, GH binding to IM 9 cells, and GH response to pharmacological stimulation. J. Clin. Endocrinol. Metab. 75: 412, 1992.
8. Reiter J-C., Craen M., Vliet G.V. Decreased growth hormone response to growth hormone-releasing hormone in Turner's syndrome: Relation to body weight and adiposity. Acta Endocrinol. (Copenh.) 125:38, 1991.
9. Khono H., Honda S. Low urinary growth hormone values in patients with Turner's syndrome. J. Clin. Endocrinol. Metab. 74: 619, 1992.
10. Ross J.L, Long L.M., Loriaux D.L., Cutler G.B. Growth hormone secretory dynamics in Turner's syndrome. J. Pediatr. 106:202, 1985.
11. Locatelli V., Torsello A., Radaelli M., Ghigo E., Massara F., Müller E.E. Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: Evidence for mediation by somatostatin. J. Endocrinol. 111: 271, 1981.
12. Richardson S.B., Hollander G.S., D'Eletto R.D., Greenleaf P.W., Than C. Acetylcholine inhibits the release of somatostatin from rat hypothalamus in vitro. Endocrinology 107: 1837, 1980.
13. Torsello A., Panzeri G., Cermenati P., Caroleo M.C., Ghigo E., Camanni F., Müller E.E., Locatelli V. Involvement of the somatostatin and cholinergic systems in the mechanism of growth hormone auto-feedback regulation in the rat. J. Endocrinol. 117: 273, 1988.
14. Ghigo E., Mazza E., Imperiale E., Rizzi G., Benso L., Müller E.E., Camanni F., Massara F. Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature. J. Clin. Endocrinol. Metab. 65: 452, 1987.
15. Spoudeas H.A., Matthews D.R., Brook C.G.D., Hindmarsh P.C. The effect of changing somatostatin tone on the pituitary growth hormone and thyroid-stimulating hormone responses to their respective releasing factor stimuli. J. Clin. Endocrinol. Metab. 75: 453, 1992.
16. Kelijiman E., Frohman L.A. The role of cholinergic pathway in growth hormone feedback. J. Clin. Endocrinol. Metab. 72: 1081, 1991.
17. Yang I., Woo J., Kim S., Kim J., Kim Y., Choi Y. Combined pyridostigmine-thyrotropin-releasing hormone test for the evaluation of hypothalamic somatostatinergic activity in healthy normal men. Eur. J. Endocrinol. (Copenh). 133: 457,1995.
18. Hanew K., Utsumi A., Sugawara A., Shimizu Y., Ikeda H., Abe K. The evaluation of hypothalamic somatostatin tone using pyridostigmine and thyrotropin releasing hormone in patients with acromegaly. J. Endocrinol. Invest. 17: 313, 1994.
19. Utumi A., Murakami O., Sugawara A., Shimizu Y., Hanew K. Cholinergic involvement in growth hormone and thyroid-stimulating hormone secretion: studies in normal short children and normal adults. Clin. Endocrinol. (Tokyo) 40: 733, 1992.
20. Hanew K., Tanaka A., Utsumi A., Sugawara A., Abe K. Plasma GH responses to human GHRH-antagonist in normal subjects Eur. J. Endocrinol. 134: 67, 1996.
21. Lukaski H.C. Methods for the assessment of human body composition: Traditional and new. Am. J. Clin. Nutr. 46: 537, 1987.
22. Schober E., Frisch H., Waldhauser F., Bieglmayr Ch. Influence of estrogen administration on growth hormone response to GHRH and L-dopa in patients with Turner's syndrome. Acta Endocrinol. (Copenh.) 120: 442, 1989.
23. Hanew K., Tanaka A., Utsumi A., Sugawara A., Abe K. The inhibitory effects of growth hormone-releasing hormone (GHRH)-antagonist on GHRH, L-dopa and clonidine-induced GH secretion in normal subjects. J. Clin. Endocrinol. Metab. 81: 1952, 1996.
24. Hizuka N., Takano K., Shizume K., Hirose N., Ling N. Plasma growth hormone responses to repetitive administrations of growth hormone releasing factor in patients with pituitary dwarfism. Endocrinol. Jpn. 37: 697, 1984.
25. Chihara K., Kashio Y., Abe H., Minamitani N., Kaji H. Kita T., Fujita T. Idiopathic growth hormone (GH) deficiency, and GH deficiency secondary to hypothalamic germinoma: effect of single and repeated administration of human GH -releasing factor (hGRF) on plasma GH level and endogenous hGRF-like immunoreactivity level in cerebrospinal fluid. J. Clin. Endocrinol. Metab. 60: 269, 1985.
26. Ghigo E., Gotti S., Nicolosi M., Arvat E. Valante F., Mazza E., Ghigo M.C., Camanni F. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. Clim. Endocrinol. Metab. 71: 1481, 1990.
27. Ghigo E., Bellone J., Mazza E., Imperiale E., Procopio M., Valente F., Lala R., De Sanctis C., Camanni F. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine. Clin. Endocrinol. 32: 763, 1990.
28. Jaffe C.A., DeMott-Friberg R., Barkan A.L. Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli. J. Clin. Invest. 97: 934, 1996.
29. 2. Biochem. Biophys. Res. Commun. 113: 588, 1982.
30. 3 cells. Biochem. Biophys. Res. Commun. 127: 986, 1985.
31. Shupnik M.A., Greenspan S.L., Ridgway E.L. Transcriptional regulation of thyrotropin subunit genes by thyrotropin-releasing hormone and dopamine in pituitary cell culture. J. Biol. Chem. 261: 12675, 1986.
32. Rebecchi M.J., Kolesnick R.N., Gershengorn M.C. TRH stimulates rapid loss of phosphatidylinositol and its conversion to 1,2-diacyl-glycerol and phosphatidic acid in rat mammotrophic pituitary cells. J. Biol. Chem. 258: 227, 1983.
33. Hanew K., Utsumi A., Sugawara A., Shimizu Y., Abe K. Enhanced GH responses to combined administration of GHRP and GHRH in patients with acromegaly. J. Clin. Endocrinol. Metab. 78: 509, 1994.